# AKT2

## Overview
AKT2 is a gene that encodes the protein AKT serine/threonine kinase 2, a member of the serine/threonine kinase family, which plays a pivotal role in various cellular processes, including glucose metabolism, cell survival, and mitochondrial homeostasis. The AKT2 protein is integral to the insulin signaling pathway, where it facilitates glucose uptake by promoting the translocation of glucose transporter type 4 (Glut4) to the plasma membrane (Cho2001Insulin). Structurally, AKT2 comprises a pleckstrin homology (PH) domain, a central kinase domain, and a regulatory C-terminal region, which are essential for its activation and function (Elangeeb2023In; Cheng1992AKT2). The protein's activity is regulated through post-translational modifications, such as phosphorylation, which are crucial for its role in cellular signaling pathways (Facchinetti2008The). Mutations in the AKT2 gene have been linked to metabolic disorders, including insulin resistance and diabetes, underscoring its significance in maintaining metabolic homeostasis (Arya2014Activating; Manning2017A).

## Structure
The AKT2 protein, encoded by the AKT2 gene, is a serine/threonine kinase involved in various cellular processes. Its primary structure consists of 481 amino acids, featuring a pleckstrin homology (PH) domain, a central kinase domain, and a regulatory C-terminal region (Elangeeb2023In; Cheng1992AKT2). The PH domain is crucial for membrane anchoring and interaction with other proteins, playing a significant role in AKT2 activation (Mitsuuchi1999Identification). The kinase domain contains 11 conserved subdomains typical of protein kinases, facilitating its catalytic activity (Cheng1992AKT2).

The tertiary structure of AKT2 includes a hydrophobic motif (HM) in the C-terminal region, which is essential for its regulation and activation. This motif interacts with the PIF-pocket on the catalytic domain, contributing to the protein's activation (Plotz2020Alternative). Post-translational modifications, particularly phosphorylation at specific sites like Thr309 and Ser474, are critical for AKT2's activation and function (Facchinetti2008The).

AKT2 also has splice variant isoforms, such as AKT2-13a, which lacks the HM regulatory site, resulting in altered regulation and reduced activity compared to the wild-type protein (Plotz2020Alternative). These structural features and modifications are vital for AKT2's role in cellular signaling pathways.

## Function
AKT2, also known as protein kinase B beta (PKBβ), is a serine-threonine protein kinase that plays a crucial role in glucose homeostasis and insulin signaling in healthy human cells. It is primarily involved in the regulation of glucose uptake in muscle and fat cells and the suppression of hepatic glucose production, which is essential for maintaining normal blood glucose levels (Cho2001Insulin). AKT2 is activated as part of the insulin signaling pathway, where it facilitates the translocation of glucose transporter type 4 (Glut4) to the plasma membrane, promoting glucose uptake (Santi2010The).

In addition to its role in glucose metabolism, AKT2 is involved in maintaining mitochondrial homeostasis. It is primarily localized to the mitochondria, where it influences mitochondrial integrity and function. Knockdown of AKT2 can lead to cell cycle arrest and increased mitochondrial volume, indicating its role in regulating mitochondrial biogenesis and preventing pathological autophagy (Santi2010The).

AKT2 is also implicated in cell survival pathways by phosphorylating and inactivating pro-apoptotic proteins, thereby preventing apoptosis and promoting cell survival (Datta1999Cellular). This kinase is active in various tissues, including the spleen and B cells, and is involved in normal cellular processes (Cheng1992AKT2).

## Clinical Significance
Mutations in the AKT2 gene are associated with several metabolic disorders. The p.Glu17Lys mutation is linked to hypoinsulinemic hypoketotic hypoglycemia and hemihypertrophy, characterized by autonomous activation of the insulin signaling pathway, leading to hypoglycemia despite undetectable serum insulin (Arya2014Activating). The Arg274His mutation results in severe insulin resistance, hyperinsulinemia, and diabetes mellitus, disrupting insulin signaling and impairing the kinase's ability to phosphorylate substrates (Arya2014Activating; George2004A). Other rare alleles, such as Arg208Lys and Arg467Trp, have been observed in individuals with severe insulin resistance (Manning2017A).

The AKT2 Pro50Thr variant, enriched in the Finnish population, is associated with increased fasting insulin levels and a modest increase in type 2 diabetes risk. This variant is characterized as a partial loss-of-function mutation, affecting insulin signaling and glucose homeostasis (Manning2017A). In mice, the absence of Akt2 leads to severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency, highlighting its critical role in glucose metabolism and adipose tissue maintenance (Garofalo2003Severe). These findings underscore the importance of AKT2 in maintaining normal metabolic functions and its potential contribution to metabolic diseases when mutated.

## Interactions
AKT2, a serine/threonine kinase, is involved in various protein interactions that play significant roles in cellular signaling pathways. One notable interaction is with the adaptor protein APPL, which contains a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain, and a leucine zipper motif. APPL interacts with the inactive form of AKT2, potentially tethering it to the PI3K catalytic subunit p110a in the cytoplasm, facilitating its recruitment to the cell membrane upon stimulation (Mitsuuchi1999Identification).

AKT2 also interacts with the POSH protein, a scaffold for the JNK signaling pathway. This interaction occurs specifically with the third SH3 domain of POSH and involves two proline-rich motifs in AKT2. The binding of AKT2 to POSH negatively regulates the assembly of the POSH-MLK3-JNK signaling complex, affecting the phosphorylation status of MLK3 and modulating JNK pathway activity (Figueroa2003Akt2).

In the context of glucose metabolism, AKT2 phosphorylates Synip at serine 99, a process crucial for the insulin-stimulated dissociation of Synip from Syntaxin4. This interaction is essential for the docking and fusion of GLUT4-containing vesicles, highlighting AKT2's specific role in insulin signaling (Yamada2005Akt2).


## References


[1. (Santi2010The) Stacey A. Santi, Alison C. Douglas, and Hoyun Lee. The akt isoforms, their unique functions and potential as anticancer therapeutic targets. BioMolecular Concepts, 1(5–6):389–401, December 2010. URL: http://dx.doi.org/10.1515/bmc.2010.035, doi:10.1515/bmc.2010.035. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/bmc.2010.035)

[2. (Cheng1992AKT2) J Q Cheng, A K Godwin, A Bellacosa, T Taguchi, T F Franke, T C Hamilton, P N Tsichlis, and J R Testa. Akt2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences, 89(19):9267–9271, October 1992. URL: http://dx.doi.org/10.1073/pnas.89.19.9267, doi:10.1073/pnas.89.19.9267. This article has 545 citations.](https://doi.org/10.1073/pnas.89.19.9267)

[3. (Yamada2005Akt2) Eijiro Yamada, Shuichi Okada, Tsugumichi Saito, Kihachi Ohshima, Minoru Sato, Takafumi Tsuchiya, Yutaka Uehara, Hiroyuki Shimizu, and Masatomo Mori. Akt2 phosphorylates synip to regulate docking and fusion of glut4-containing vesicles. The Journal of Cell Biology, 168(6):921–928, March 2005. URL: http://dx.doi.org/10.1083/jcb.200408182, doi:10.1083/jcb.200408182. This article has 71 citations.](https://doi.org/10.1083/jcb.200408182)

[4. (Datta1999Cellular) S. R. Datta, A. Brunet, and M. E. Greenberg. Cellular survival: a play in three akts. Genes &amp; Development, 13(22):2905–2927, November 1999. URL: http://dx.doi.org/10.1101/gad.13.22.2905, doi:10.1101/gad.13.22.2905. This article has 3284 citations.](https://doi.org/10.1101/gad.13.22.2905)

[5. (Elangeeb2023In) M. E. Elangeeb, Imadeldin Elfaki, M. A. Elkhalifa, Khalid M. Adam, A. O. Alameen, Ahmed Kamaleldin Elfadl, Ibrahim Altedlawi Albalawi, Kholoud S. Almasoudi, Reema Almotairi, Basim S. O. Alsaedi, Marwan H. Alhelali, Mohammad Muzaffar Mir, Dnyanesh Amle, and Rashid Mir. In silico investigation of akt2 gene and protein abnormalities reveals potential association with insulin resistance and type 2 diabetes. Current Issues in Molecular Biology, 45(9):7449–7475, September 2023. URL: http://dx.doi.org/10.3390/cimb45090471, doi:10.3390/cimb45090471. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cimb45090471)

[6. (Manning2017A) Alisa Manning, Heather M. Highland, Jessica Gasser, Xueling Sim, Taru Tukiainen, Pierre Fontanillas, Niels Grarup, Manuel A. Rivas, Anubha Mahajan, Adam E. Locke, Pablo Cingolani, Tune H. Pers, Ana Viñuela, Andrew A. Brown, Ying Wu, Jason Flannick, Christian Fuchsberger, Eric R. Gamazon, Kyle J. Gaulton, Hae Kyung Im, Tanya M. Teslovich, Thomas W. Blackwell, Jette Bork-Jensen, Noël P. Burtt, Yuhui Chen, Todd Green, Christopher Hartl, Hyun Min Kang, Ashish Kumar, Claes Ladenvall, Clement Ma, Loukas Moutsianas, Richard D. Pearson, John R.B. Perry, N. William Rayner, Neil R. Robertson, Laura J. Scott, Martijn van de Bunt, Johan G. Eriksson, Antti Jula, Seppo Koskinen, Terho Lehtimäki, Aarno Palotie, Olli T. Raitakari, Suzanne B.R. Jacobs, Jennifer Wessel, Audrey Y. Chu, Robert A. Scott, Mark O. Goodarzi, Christine Blancher, Gemma Buck, David Buck, Peter S. Chines, Stacey Gabriel, Anette P. Gjesing, Christopher J. Groves, Mette Hollensted, Jeroen R. Huyghe, Anne U. Jackson, Goo Jun, Johanne Marie Justesen, Massimo Mangino, Jacquelyn Murphy, Matt Neville, Robert Onofrio, Kerrin S. Small, Heather M. Stringham, Joseph Trakalo, Eric Banks, Jason Carey, Mauricio O. Carneiro, Mark DePristo, Yossi Farjoun, Timothy Fennell, Jacqueline I. Goldstein, George Grant, Martin Hrabé de Angelis, Jared Maguire, Benjamin M. Neale, Ryan Poplin, Shaun Purcell, Thomas Schwarzmayr, Khalid Shakir, Joshua D. Smith, Tim M. Strom, Thomas Wieland, Jaana Lindstrom, Ivan Brandslund, Cramer Christensen, Gabriela L. Surdulescu, Timo A. Lakka, Alex S.F. Doney, Peter Nilsson, Nicholas J. Wareham, Claudia Langenberg, Tibor V. Varga, Paul W. Franks, Olov Rolandsson, Anders H. Rosengren, Vidya S. Farook, Farook Thameem, Sobha Puppala, Satish Kumar, Donna M. Lehman, Christopher P. Jenkinson, Joanne E. Curran, Daniel Esten Hale, Sharon P. Fowler, Rector Arya, Ralph A. DeFronzo, Hanna E. Abboud, Ann-Christine Syvänen, Pamela J. Hicks, Nicholette D. Palmer, Maggie C.Y. Ng, Donald W. Bowden, Barry I. Freedman, Tõnu Esko, Reedik Mägi, Lili Milani, Evelin Mihailov, Andres Metspalu, Narisu Narisu, Leena Kinnunen, Lori L. Bonnycastle, Amy Swift, Dorota Pasko, Andrew R. Wood, João Fadista, Toni I. Pollin, Nir Barzilai, Gil Atzmon, Benjamin Glaser, Barbara Thorand, Konstantin Strauch, Annette Peters, Michael Roden, Martina Müller-Nurasyid, Liming Liang, Jennifer Kriebel, Thomas Illig, Harald Grallert, Christian Gieger, Christa Meisinger, Lars Lannfelt, Solomon K. Musani, Michael Griswold, Herman A. Taylor, Gregory Wilson, Adolfo Correa, Heikki Oksa, William R. Scott, Uzma Afzal, Sian-Tsung Tan, Marie Loh, John C. Chambers, Jobanpreet Sehmi, Jaspal Singh Kooner, Benjamin Lehne, Yoon Shin Cho, Jong-Young Lee, Bok-Ghee Han, Annemari Käräjämäki, Qibin Qi, Lu Qi, Jinyan Huang, Frank B. Hu, Olle Melander, Marju Orho-Melander, Jennifer E. Below, David Aguilar, Tien Yin Wong, Jianjun Liu, Chiea-Chuen Khor, Kee Seng Chia, Wei Yen Lim, Ching-Yu Cheng, Edmund Chan, E Shyong Tai, Tin Aung, Allan Linneberg, Bo Isomaa, Thomas Meitinger, Tiinamaija Tuomi, Liisa Hakaste, Jasmina Kravic, Marit E. Jørgensen, Torsten Lauritzen, Panos Deloukas, Kathleen E. Stirrups, Katharine R. Owen, Andrew J. Farmer, Timothy M. Frayling, Stephen P. O’Rahilly, Mark Walker, Jonathan C. Levy, Dylan Hodgkiss, Andrew T. Hattersley, Teemu Kuulasmaa, Alena Stančáková, Inês Barroso, Dwaipayan Bharadwaj, Juliana Chan, Giriraj R. Chandak, Mark J. Daly, Peter J. Donnelly, Shah B. Ebrahim, Paul Elliott, Tasha Fingerlin, Philippe Froguel, Cheng Hu, Weiping Jia, Ronald C.W. Ma, Gilean McVean, Taesung Park, Dorairaj Prabhakaran, Manjinder Sandhu, James Scott, Rob Sladek, Nikhil Tandon, Yik Ying Teo, Eleftheria Zeggini, Richard M. Watanabe, Heikki A. Koistinen, Y. Antero Kesaniemi, Matti Uusitupa, Timothy D. Spector, Veikko Salomaa, Rainer Rauramaa, Colin N.A. Palmer, Inga Prokopenko, Andrew D. Morris, Richard N. Bergman, Francis S. Collins, Lars Lind, Erik Ingelsson, Jaakko Tuomilehto, Fredrik Karpe, Leif Groop, Torben Jørgensen, Torben Hansen, Oluf Pedersen, Johanna Kuusisto, Gonçalo Abecasis, Graeme I. Bell, John Blangero, Nancy J. Cox, Ravindranath Duggirala, Mark Seielstad, James G. Wilson, Josee Dupuis, Samuli Ripatti, Craig L. Hanis, Jose C. Florez, Karen L. Mohlke, James B. Meigs, Markku Laakso, Andrew P. Morris, Michael Boehnke, David Altshuler, Mark I. McCarthy, Anna L. Gloyn, and Cecilia M. Lindgren. A low-frequency inactivating akt2 variant enriched in the finnish population is associated with fasting insulin levels and type 2 diabetes risk. Diabetes, 66(7):2019–2032, March 2017. URL: http://dx.doi.org/10.2337/db16-1329, doi:10.2337/db16-1329. This article has 46 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db16-1329)

[7. (Facchinetti2008The) Valeria Facchinetti, Weiming Ouyang, Hua Wei, Nelyn Soto, Adam Lazorchak, Christine Gould, Carolyn Lowry, Alexandra C Newton, Yuxin Mao, Robert Q Miao, William C Sessa, Jun Qin, Pumin Zhang, Bing Su, and Estela Jacinto. The mammalian target of rapamycin complex 2 controls folding and stability of akt and protein kinase c. The EMBO Journal, 27(14):1932–1943, June 2008. URL: http://dx.doi.org/10.1038/emboj.2008.120, doi:10.1038/emboj.2008.120. This article has 418 citations.](https://doi.org/10.1038/emboj.2008.120)

[8. (Mitsuuchi1999Identification) Yasuhiro Mitsuuchi, Steven W Johnson, Gonosuke Sonoda, Satoshi Tanno, Erica A Golemis, and Joseph R Testa. Identification of a chromosome 3p14.3-21.1 gene, appl, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase akt2. Oncogene, 18(35):4891–4898, September 1999. URL: http://dx.doi.org/10.1038/sj.onc.1203080, doi:10.1038/sj.onc.1203080. This article has 170 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1203080)

[9. (Arya2014Activating) Ved Bhushan Arya, Sarah E. Flanagan, Edith Schober, Birgit Rami-Merhar, Sian Ellard, and Khalid Hussain. Activating akt2 mutation: hypoinsulinemic hypoketotic hypoglycemia. The Journal of Clinical Endocrinology &amp; Metabolism, 99(2):391–394, February 2014. URL: http://dx.doi.org/10.1210/jc.2013-3228, doi:10.1210/jc.2013-3228. This article has 29 citations.](https://doi.org/10.1210/jc.2013-3228)

[10. (Cho2001Insulin) Han Cho, James Mu, Jason K. Kim, Joanne L. Thorvaldsen, Qingwei Chu, E. Bryan Crenshaw, Klaus H. Kaestner, Marisa S. Bartolomei, Gerald I. Shulman, and Morris J. Birnbaum. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase akt2 (pkbβ). Science, 292(5522):1728–1731, June 2001. URL: http://dx.doi.org/10.1126/science.292.5522.1728, doi:10.1126/science.292.5522.1728. This article has 1473 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.292.5522.1728)

[11. (Figueroa2003Akt2) Claudia Figueroa, Samantha Tarras, Jennifer Taylor, and Anne B. Vojtek. Akt2 negatively regulates assembly of the posh-mlk-jnk signaling complex. Journal of Biological Chemistry, 278(48):47922–47927, November 2003. URL: http://dx.doi.org/10.1074/jbc.M307357200, doi:10.1074/jbc.m307357200. This article has 117 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M307357200)

[12. (Plotz2020Alternative) Guido Plotz, Laura A. Lopez-Garcia, Angela Brieger, Stefan Zeuzem, and Ricardo M. Biondi. Alternative akt2 splicing produces protein lacking the hydrophobic motif regulatory region. PLOS ONE, 15(11):e0242819, November 2020. URL: http://dx.doi.org/10.1371/journal.pone.0242819, doi:10.1371/journal.pone.0242819. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0242819)

[13. (Garofalo2003Severe) Robert S. Garofalo, Stephen J. Orena, Kristina Rafidi, Anthony J. Torchia, Jeffrey L. Stock, Audrey L. Hildebrandt, Timothy Coskran, Shawn C. Black, Dominique J. Brees, Joan R. Wicks, John D. McNeish, and Kevin G. Coleman. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking akt2/pkbβ. Journal of Clinical Investigation, 112(2):197–208, July 2003. URL: http://dx.doi.org/10.1172/jci16885, doi:10.1172/jci16885. This article has 541 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci16885)

[14. (George2004A) Stella George, Justin J. Rochford, Christian Wolfrum, Sarah L. Gray, Sven Schinner, Jenny C. Wilson, Maria A. Soos, Peter R. Murgatroyd, Rachel M. Williams, Carlo L. Acerini, David B. Dunger, David Barford, A. Margot Umpleby, Nicholas J. Wareham, Huw Alban Davies, Alan J. Schafer, Markus Stoffel, Stephen O’Rahilly, and Inês Barroso. A family with severe insulin resistance and diabetes due to a mutation in akt2. Science, 304(5675):1325–1328, May 2004. URL: http://dx.doi.org/10.1126/science.1096706, doi:10.1126/science.1096706. This article has 451 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1096706)